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Abstract. The aim of the present study was to investigate the local effect of 10% doxycycline and 1%
alendronate combined with poly(lactic-co-glycolic acid) (PLGA) on bone repair. Thirty rats were divided
into three groups, as follows: control group (CG), drug group (DG), and vehicle-PLGA group (VG).
Bone defect was created in the right femur and filled with the following: blood clot (CG); PLGA gel, 10%
doxycycline and 1% alendronate (DG); or vehicle-PLGA (VG). The animals were euthanized 7 or 15 days
after surgery. Bone density, bone matrix and number of osteoclasts were quantified. At 7 days, the findings
showed increased density in DG (177.75±76.5) compared with CG (80.37±27.4), but no difference
compared with VG (147.1±41.5); no statistical difference in bone neoformation CG (25.6±4.8), VG
(27.8±4), and DG (18.9±7.8); and decrease osteoclasts in DG (4.6±1.9) compared with CG (26.7±7.4)
and VG (17.3±2.7). At 15 days, DG (405.1±63.1) presented higher density than CG (213.2±60.9) and VG
(283.4±85.8); there was a significant increase in percentage of bone neoformation in DG (31.5±4.2)
compared with CG (23±4), but no difference compared with VG (25.1±2.9). There was a decreased
number of osteoclasts in DG (20.7±4.7) and VG (29.5±5.4) compared with CG (40±9.4). The results
suggest that the association of 10% doxycycline and 1% alendronate with PLGA-accelerated bone repair.
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INTRODUCTION
Bone repair and reconstruction of large defects are chal-
lenges to clinical therapies in several areas of medicine. Bone
tissue regeneration is a complex sequence of events that be-
gins with the recruitment, attachment, and proliferation of
progenitor cells, followed by cell differentiation into pheno-
types capable of restoring the damaged tissue (1).
At present, bone repair strategies have been explored,
using factors that stimulate osteogenesis (2), such as bone
morphogenetic protein 2 (BMP-2) (3), basic fibroblast growth
factor (b-FGF) (4), platelet-rich plasma (PRP) (5),
transforming growth factor-beta 1 (TGF-β1) (6), and vascular
endothelial growth factor (VEGF) (7). Recent investigations
have shown that different classes of drugs, such as
bisphosphonates, tetracyclines, and their combination, stimu-
late osteogenesis when their use was evaluated with regard to
alveolar bone loss in periodontitis (8–10), healing of bone
defects (1) and in vitro cell culture (11,12).
Bisphosphonates have an anabolic effect on osteoblasts
(13–16), improving proliferation and maturation (11,17),
inhibiting apoptosis (16), and considering the aforementioned
actions, and could result in increased bone formation (11,17).
Bisphosphonates are well-known inhibitors of osteoclastic ac-
tivity and are widely used to treat osteoporosis; among them,
alendronate is one of the most potent anti-osteoporotic agents
known (18). Studies have shown that locally delivered
alendronate has an effect on increased bone repair in a
critical-sized calvarial defect (19) and peri-implant bone for-
mation (20) and associated with bone allografts (21). More-
over, alendronate enhances alkaline phosphatase (ALP)
activity and bone neoformation (19).
Semi-synthetic tetracyclines, such as the administration of
doxycycline in either local or systemic sub-antimicrobial
doses, have been studied to minimize host tissue breakdown.
In periodontal surgery, Doxycycline has been shown to im-
prove wound healing, to increase osteogenic mediators, and to
reduce collagenase (22). Recently, the benefits of doxycycline
as an osteogenic agent was observed on the surface of bone
implants (23), in healing of oral infrabony defects (24) and
osteoclastogenesis downregulation in vitro (25).
Poly(lactic-co-glycolic acid) (PLGA) has been used as a
delivery vehicle for almost all types of antibiotics, due to its
tunable degradation profile and biocompatible degradation
products (26). Several studies have reported the release of
antibiotics from PLGA to occur over the span of weeks to
months (27,28). Antibiotic-loaded PLGA has also been incor-
porated into tissue engineering scaffolds for the purpose of
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mitigating infection, and release has been reported to occur
over 8 weeks in vitro (27).
In the present study, it was hypothesized that association
of the anabolic properties of alendronate (12) with the antibi-
otic and anti-proteolytic properties of doxycycline (29) com-
bined with the delivery system of PLGA (30,31) would
increase bone neoformation and accelerate bone repair. The
null hypothesis tested was that local delivery of 10% doxycy-
cline and 1% alendronate in PLGAwould not affect the repair
of experimental bone defects in rats at 7 and 15 days.
MATERIAL AND METHODS
Experimental Procedure
The sample consisted of 30 healthy male Wistar rats
(Rattus norvegicus), weighing 250 to 300 g. The animals were
kept in cages, in a 12-h:12-h light-dark cycle, and controlled
temperature conditions (22±2°C), with standard food and
water ad libitum. This study was previously approved by the
Science and Ethics Committee from Federal University of
Uberlândia, Brazil, Protocol 022/12, and was performed in
accordance with the Brazilian College for Animal Experimen-
tation (COBEA). The animals were randomly divided into
three groups, with each group being composed of five animals,
as follows: control group (CG), Clot; drug group (DG), 10%
doxycycline and 1% alendronate in PLGA; vehicle group
(VG), only PLGA. The animals were euthanized after 7 or
15 days.
All animals were submitted to osteotomy in the right
femur to create a bone defect, after being anesthetized with
intraperitoneal injection of 2% ketamine ratio 100 mg/kg and
10% xylazine hydrochloride ratio 3 mg/kg. They were placed
in the left lateral decubitus position, and access to bone was
achieved by making a continuous longitudinal incision of 2 cm,
exposing the mid-diaphysis. A standardized 2.3-mm diameter
osteotomy was performed with a round bur under saline solu-
tion irrigation. The drilling depth limit was disruption of the
femoral cortical bone. In CG, the defect was filled only with
blood clot; in DG, the defect was filled with 10 μL of gel
composed of 10% (1000 μg) doxycycline (Neo-química,
Anápolis, MG, Brazil) and 1% (100 μg), alendronate (Neo-
química, Anápolis, MG, Brazil) in PLGA, and VG the defect
was filled with 10 μl of vehicle-PLGA (lactide/glycolide ratio
50/50, Mw=40,000–75,000). The drugs and PLGAwere mixed
with Misonix Sonicator (Microson XL 2000, Misonix Incorpo-
rated, Farmingdale, NY, USA). After this, soft tissues were
repositioned and suturing was performed in muscle and cuta-
neous layers using nylon 4–0. After 7 and 15 days, the animals
were euthanized. The femurs were removed, fixed in 10%
phosphate buffer formaldehyde solution for 48 h, and kept
in phosphate buffer solution until analysis was performed.
Computed Tomographic Analysis
The femurs were positioned perpendicular to the basal
surface and scanned in a Cone-Beam 3D scanner (Gendex,
GX-CB500-ICAT) at 7 mA, 120 kvp, and 0.125 voxel resolu-
tion. From each specimen, three tomographic images of the
region of interest (ROI) within the bone defect were selected.
In these images, the bone defect was delimited with a
rectangle. Two squares measuring 0.1 mm2 were marked in
the cortical and medullary region to serve as maximum and
minimum reference values achieved in the same image. In
addition, the blood, drugs and vehicle-PLGA were placed in
Eppendorf tubes and were scanned to obtain the individual
radiodensity. The Hounsfield scale of regions and materials
was obtained using specific software (i-CAT® Vision, Imaging
Sciences International, Penn Road, Hatfield, PA).
Histologic and Histomorphometric Analysis
After computed tomographic (CT) analysis, the speci-
mens were decalcified in 10% EDTA, dehydrated with series
of graded ethanol and embedded in paraffin. The 5-μm longi-
tudinal histological sections obtained were stained with hema-
toxylin and eosine (HE) and Mallory trichrome. For
quantifying bone matrix neoformation, histological images of
the bone defect were captured, using a binocular microscope
Nikon Eclipse E2000 (Nikon®, Nikon do Brasil, São Paulo,
Brazil) coupled to a Moticam Pro 252B camera (Motic®,
British Columbia, Canada) and the software Motic Live Im-
aging Module (Motic®, British Columbia, Canada). The
screen shots were merged, soft tissue was erased using
Photoshop CS6 software (Adobe®, Adobe System Inc., San
Jose, CA/USA), and finally, they were converted into binary
images with HL Image 2005++ (Western Vision, Salt Lake
City, UT, USA). The ROI was delineated with four straight
lines from the defect of the cortical bone up to the internal
surface to the opposite cortical. The percentage of bone ma-
trix neoformation within the ROI was calculated with HL
Image 2005.
Of the HE-stained specimens, 180 histological images of
ROI were analyzed in each group, of every period. The im-
ages were obtained using Leica® DM2500 M Microscope
(Leica Microsystems®, Buffalo Grove, Illinois, USA)≥. Two
blinded examiners counted all the osteoclasts present in the
ROI considering cells that presented with greater that or
equal to two nuclei, associated with the bone resorption sur-
face (32). Any disagreements between the two examiners
were resolved by a third examiner. The inter-reviewer reliabil-
ity of data extraction was calculated by determining the per-
centage of agreement and the correlation coefficient (kappa,
5% level of significance).
Statistical Analysis
Analysis was performed using statistical software
GraphPad Prism (version 5.0 for Windows, San Diego, CA,
USA). The results obtained were submitted to the Shapiro-
Wilk normality test and Two-Way Anova followed by the
Tukey test. Differences were considered statistically signifi-
cant when α<0.05.
RESULTS
After the surgery, all animals showed normal behavior;
they lost no weight and wound healing progressed without any
signs of infection.
CT analysis showed there was no significant difference in
the bone radiodensity at the cortical (Fig. 1a) and medullar
reference between the femurs among the groups (Fig. 1b).
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However, the ROI analysis showed increased density in DG
(177.75±76.5) compared with CG (80.37±27.4), but no differ-
ence compared VG (147.1±41.5) with DG and CG at 7 days.
After 15 days, DG (405.1±63.1) presented higher density than
CG (213.2±60.9) and VG (283.4±85.8) (Fig. 1d) (P<0.05).
Histologic analysis in the photomicrograph of femur lon-
gitudinal section at 7 days showed similar bone healing in CG
and VG. In these groups, the ROI was almost filled by prima-
ry bone (PB) and periosteum was reasonably well cellularized
with many fusiform cells between collagens fibers. Around
collagen fibers, granulation tissue (GT) and blastema
regeneration were observed, characterized by intense prolif-
eration and differentiation of mesenchymal cells. In DG, the
ROI was almost totally occupied by blood clots (BC) with
large areas of fibrin network. At the periphery, there was
chronic inflammatory infiltration with giant cells, and dilated
vessels with many leukocytes. Around the inflammation, there
was granulation tissue (GT) and incipient primary bone (PB).
The periosteum was cellularized with few fibers between the
cells (Fig. 2).
At 15 days, in CG and VG, histological analysis showed
ROI filled by primary bone (PB) with thinner trabecular bone
Fig. 1. Bone radiodensity references in cortical a and medullar b areas. Computed tomographic image demonstrating the
region of interest (ROI) delineation c. Bone radiodensity in ROI all evaluated groups (d) (*P<0.05)
Fig. 2. Photomicrograph of femur longitudinal section of all groups. Cortical (C). Medullary tissue (M). Primary bone (PB). Granulation tissue
(GT). Trabecular bone (TB). Blood cot (BC). Giant cell (arrow). Hematoxylin and eosin
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(TB) and large spaces between them, filled with medullary
tissue (M). DG showed bone neoformation similar to CG and
VG. However, in DG, primary bone (PB) tissue filled the
defect area and extended largely into the medullary channel;
also, the trabecular bone (TB) were thicker, especially in
comparison with CG (Fig. 2).
The histomorphometric analysis at 7 days showed no
statistical difference between the groups CG (25.6±4.8), VG
(27.8±4), and DG (18.9±7.8). However, statistical analysis
showed a significant increase in the percentage of bone
neoformation in DG (31.5±4.2) when compared with CG
(23±4), but no difference when VG (25.1±2.9) was compared
with DG and CG at 15 days (P<0.05) (Fig. 3).
The number of osteoclasts in DG (4.6±1.9) decreased
compared with CG (26.7±7.4) and VG (17.3±2.7) at 7 days.
There was an increased number of osteoclasts between CG
(40±9.4) compared with DG (20.7±4.7) and VG (29.5±5.4) at
15 days (P<0.05) (Fig. 4). Agreement with kappa value=0.89
was obtained between the examiners about the number of
osteoclasts.
DISCUSSION
The null hypothesis was rejected. The local delivery of
10%doxycycline and 1% alendronate gel affected the repair
of experimental bone defects in rats at seven and fifteen days.
Bone repair, a challenge in areas of medicine, is a complex
process involving the action of systemic and locally produced
growth factors, hormones, and vitamins and a delicate balance
between osteoblasts and osteoclasts (33).
In the present study, the association between alendronate,
doxycycline and PLGA (DG) showed an increase in the per-
centage of bone neoformation at fifteen days. This result might
be attributable to the anti-collagenolytic effect of doxycycline,
which enhances the bone-forming ability via osteoblast cell
chemotaxis and reduces bone resorption via osteoclasts (34).
In vivo periodontal studies have shown that combined therapy
with alendronate and/or doxycycline leads to a reduction in hard
tissue destruction, inhibition and down-regulation of matrix
metalloproteinase (8,9).
The decrease osteoclasts inDG could be due to the effect of
RANKL down-regulation (35) osteoclast inhibition by
alendronate (13–15,18). Moreover, in order to inhibit bone
resorption by osteoclasts, bisphosphonates also have an anabol-
ic effect on osteoblasts (36). Studies have shown that numerous
bisphosphonates (olpadronate, pamidronate, etidronate) in-
duced osteoblast proliferation. Im et al. (11) investigated the
effects of alendronate and risedronate on primary human tra-
becular bone cell cultures, in MG-63 osteoblast-like cell lines,
and found that bisphosphonates promoted osteoblast prolifera-
tion andmaturation, as shown by increased cell numbers and the
enhanced expression of bone morphogenetic protein BMP-2,
type I collagen, and osteocalcin.
The chronic inflammatory infiltration with multinucleat-
ed giant cells at 7 days found in DG could be due to the low
pH (3,7) of the drug. The treatment with biomaterials was
shown to be immunogenic for tissue in some studies, and the
main etiological mechanism was the decrease in local pH and
induction of host immunoreactivity (37).
Yaffe et al. (10) showed that local delivery of doxycycline
with alendronate had no additive effect on alveolar bone loss.
The author explained this result by the high concentration
(10%) of doxycycline in the preparation. However, the pres-
ent study showed positive results with this concentration,
probably due to the drug administration by the vehicle-
PLGA, which decreased the high concentration and reduced
contact between the tissue and drugs (30,31). The 10% of
doxycycline has been used in several commercially available
agents with positive results in bone formation (38) and
alendronate can be applied topically in lower doses to locally
inhibit bone resorption (39).
PLGAprovides a wide range of advantages, such as a smaller
particle size that facilitates penetration into the cells, higher entrap-
ment efficiency for increased drug release, lower minimum
Fig. 3. Percentage of bone neoformation in CG (control group), DG
(drug group), and VG (vehicle group) at 7 and 15 days (*P<0.05)
Fig. 4. aMorphologic osteoclast. b Number of osteoclasts in CG (control group), VG (vehicle group), and DG (drug
group) at 7 and 15 days (*P<0.05)
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inhibitory concentration, and minimum bacterial concentrations,
meaning that a better antibacterial activity was achieved with a
smaller amount of drug (30,31). The present study provided evi-
dence that a PLGAshowed an interactionwith bone repairwhen it
was used as a filling material in bone defects. An in vitro study has
shown that when in contact with a PLGA, human osteoblastic cells
secrete extracellular matrix components such as collagen, fibronec-
tin, and glycoproteins. Then, this organic extracellular matrix is
used to support the osteoblast adhesion via receptors known as
integrins (40).
CT showed that radiodensity increased at 7 and 15 days in
DG. The results showed higher radiodensity in the DG group at
15 days, confirming the results found in the histomorphometric
analyses. At 7 days, the results were controversial when com-
pared with the histomorphometric analyses; however, a CT scan
of the materials (blood, drugs, and vehicle) showed that in asso-
ciation with alendronate, doxycycline and PLGA had higher
radiodensity than blood clots. Despite the limitation of the reso-
lution of CTscans, whichmay have contributed to degradation of
the grayscale fidelity of the final image displayed, it still provided
important information about density in our study (41).
CONCLUSION
The results of this study suggest that the association of 10%
doxycycline, 1% alendronate, and PLGA accelerates bone repair
when compared with defects filled with blood clot or only vehicle-
PLGA.These finding could have significant clinical implications in
bone reconstructive surgical procedures.
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